Citations (10)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (3)
Jameela Banu. (2013) Causes, consequences, and treatment of osteoporosis in men. Drug Design, Development and Therapy 7, pages 849-860.
Read now
Read now
Concepcion De La Piedra, I. Quiroga, M. Montero, S. Dapia, J. R. Caeiro, M. Rubert, M. Diaz-Curiel & F. Bauss. (2011) Daily or monthly ibandronate prevents or restores deteriorations of bone mass, architecture, biomechanical properties and markers of bone turnover in androgen-deficient aged rats. The Aging Male 14:4, pages 220-230.
Read now
Read now
Ronald C Hamdy. (2010) Zoledronic acid: clinical utility and patient considerations in osteoporosis and low bone mass. Drug Design, Development and Therapy 4, pages 321-335.
Read now
Read now
Articles from other publishers (7)
Ji Hoon Bahk, Woo-Lam Jo, Soon-Yong Kwon, Hyung Chul Park & Young Wook Lim. (2023) Weight-Based Bisphosphonate Administration for Multiple Myeloma Patients and the Risks of Skeletal Complications. Journal of Clinical Medicine 12:4, pages 1637.
Crossref
Crossref
Zhiyuan Lu, Dawei Wang, Xuming Wang, Jilong Zou, Jiabing Sun & Zhenggang Bi. (2021) MiR-206 regulates the progression of osteoporosis via targeting HDAC4. European Journal of Medical Research 26:1.
Crossref
Crossref
Wenhan Zhao, Zhusong Huang, Yu Lin, Jinfu Lan & Xi Gao. (2021) Inhibition Effect of Zoledronate on the Osteoclast Differentiation of RAW264.7 Induced by Titanium Particles. BioMed Research International 2021, pages 1-7.
Crossref
Crossref
Jéssica S. Barbosa, Filipe A. Almeida Paz & Susana Santos Braga. (2021) Bisphosphonates, Old Friends of Bones and New Trends in Clinics. Journal of Medicinal Chemistry 64:3, pages 1260-1282.
Crossref
Crossref
Kishan Patel, Emma Walshaw & Charolene Aranha. (2020) Medication-related osteonecrosis of the jaw. InnovAiT: Education and inspiration for general practice 13:4, pages 207-212.
Crossref
Crossref
Ieva Ruza, Sasan Mirfakhraee, Eric Orwoll & Ugis Gruntmanis. (2013) Clinical experience with intravenous zoledronic acid in the treatment of male osteoporosis: evidence and opinions. Therapeutic Advances in Musculoskeletal Disease 5:4, pages 182-198.
Crossref
Crossref
Sheila Anne Doggrell. (2010) Zoledronic Acid Once-yearly: What Role in the Prevention of Non-vertebral Osteoporotic Fractures?. Clinical Medicine Insights: Therapeutics 2, pages CMT.S4947.
Crossref
Crossref